spacer
home > directory > CMAB Biopharma
PHARMACEUTICAL INDUSTRY DIRECTORY

CMAB Biopharma

CMAB Biopharma
CMAB Biopharma is a full service, pure play Contract Development and Manufacturing Organisation (CDMO), which provides bespoke solutions for mammalian cell culture derived antibodies and recombinant proteins.

Our mission is to be the biologic CDMO of choice for biopharma companies from around the world by leveraging our state-of-the-art manufacturing facility, our large-scale production capacity and our ability to meet international quality requirements.

Established in 2017 with strong financial backing from our three main shareholders (C-Bridge Capital, CD Capital and BioBay), our 10,500 m2 (112,980 ft2) facility is located just outside of Shanghai in Suzhou, China. We have grown rapidly in 18 months to 175 full time employees with international offices founded in Switzerland, Toronto and Singapore. Our senior management is composed of experts with experience working in large international biotechnology organisations such as Genentech, Eli Lilly, Pfizer, Amgen and Janssen as well as CDMOs such as Lonza, Wuxi, Therapure and MabPlex.

At CMAB Biopharma, we currently provide expertise and experience in cell line development, process and analytical development, drug substance (DS) CGMP manufacturing as well as fully automated aseptic fill / finish along with lyophilisation. Our process development and analytical development labs are fully equipped with the latest equipment including a mass spectrometer unit for protein characterisation. Our four parallel upstream suites offer flexible CGMP production scales using multiple single use bioreactors (SUBs) ranging from 200 to 2,000 L volumes. Finally, we can provide our clients with lot release testing and standardised stability studies.

Our operational protocols and quality standards comply fully with FDA, EMA and NMPA guidelines, which enables CMAB Biopharma to produce CGMP material for both domestic as well as global clients. In addition, our quality standards align to the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S), International Committee on Harmonization (ICH) and World Health Organisation (WHO) guidelines.

To learn more about CMAB Biopharma or to get in contact with us directly, please visit www.cmabbio.com/en or write to us at hello@cmabbio.com. We look forward to hearing from you.
phone (+86) 0512 6799 5188
email hello@cmabbio.com
web www.cmabbio.com/en
email Building C37, No. 188 Dong Ping Road, Suzhou Industrial Park, China 215123
 
spacer

Member login

E-mail address:

Password:
Remember me

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement